Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Omzet Thrombo daalt van 22,8 naar 13,8 miljoen: Wat een geweldig bedrijf...!!!
Volgen
Euronext Brussel: Ook Thrombogenics (+3,6%, 4,42 euro) was in goede doen. Eerder deze week bleek dat shorters, die speculeerden op een koersdaling, hun posities moesten afsluiten. Sinds begin deze maand is het aandeel al zowat de helft in waarde gestegen.
Thrombogenics op Kanaal Z.kanaalz.knack.be/beurs/z-beurs-1 ... 05859.html
Ik krijg hem niet geopend
Ik heb het ff bekeken , bedankt
waarom zo hard naar beneden?
dréke schreef op 20 september 2015 13:50 :
kanaalz.knack.be/beurs/z-beurs-16-09-... AB tje verdient, je 1e. Ik hoop dat je er nog vele mag scoren :) thks.
ThromboGenics presenteert nieuwe vitreo-retinal onderzoeksresultaten op Europese vereniging voor de zitting van de visie en oog onderzoek (ooit)5 oktober www.thrombogenics.com/sites/defa ... inal_2.pdfhttp://www.thrombogenics.com/sites/defa ... inal_2.pdfGa voor meer informatie over de hierboven genoemde onderwerpen, de pagina van het onderzoek van de ThromboGenics website.Dr. Patrik De Haes, ThromboGenics' CEO, zei: "ThromboGenics is toegewijd om kwalitatief hoogwaardig fundamenteel onderzoek op het gebied van oftalmologie zoals blijkt uit deze bevindingen die zal worden gepresenteerd tijdens de komende conferentie over EVER. Het is dit soort onderzoek dat onze voortdurende interne ontwikkeling van een aantal potentieel volgende-generatie oftalmologie producten informeert.http://www.thrombogenics.com/content/th ... ion-vision - Se
Je bedoelt dit art. ThromboGenics presenting new vitreo-retinal research findings at European Association for Vision and Eye Research (EVER) meeting 5 Oct 2015 Leuven, October 5, 2015 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the Company will be presenting three scientific posters at the upcoming European Association for Vision and Eye Research (EVER) conference, October 7-10th in Nice, France. • Dr. Tine Van Bergen of ThromboGenics will present a poster entitled: Complementary effects of PIGF inhibition and MMC in the improvement of surgical outcome after glaucoma filtration surgery. The data indicate that placental growth factor (PlGF) neutralization in combination with mitomycin-C (MMC) have complementary effects in the improvement of surgical outcome by reducing the fibrosis in the bleb. • Ir. Isabelle Etienne of ThromboGenics will present a poster entitled: Posterior Vitreous Detachment: more a case of the fibronectin interface than the inner limiting membrane? The outcome of the study indicates that only minimal quantitative changes are observed for the presence of collagen, laminin and fibronectin in the inner limiting membrane (ILM) and the posterior vitreous interface after the induction of posterior vitreous detachment (PVD) by an ocriplasmin analogue in animal models. • Dr. Koen Willekens of UZ, Ophthalmology, Leuven will present a poster entitled: Imaging of intravitreal injected fluid dispersion. The poster covers a study evaluating optimized minimally invasive imaging methods for studying drug dispersion within the vitreous body. The findings of this study are important as the activity of an intravitreal drug is linked to its dispersion within the vitreous body. Studies were performed in collaboration with the department of Radiology, UZ Leuven and ThromboGenics. For more information on the above mentioned subjects, please go the research page of the ThromboGenics website. Dr. Patrik De Haes, ThromboGenics’ CEO, said: “ThromboGenics is committed to high-quality fundamental research in the field of ophthalmology as demonstrated by these findings which will be presented at the upcoming EVER conference. It is this type of research that informs our continuing internal development of a number of potentially next-generation ophthalmology products.”www.thrombogenics.com/sites/default/f... www.thrombogenics.com/science/research en click door super products. Gaat goed komen met Trombo. LZA
ThromboGenics Business Update – Q3 2015 5 Nov 2015 US organization adapted for break-even from 2016 onwards Since launch, 20,000 patients treated globally with JETREA® Diabetic Eye Disease clinical/ pre-clinical programs on track Cash to support current development plans for the next 3 years Highlights JETREA® in the US • ThromboGenics has adjusted the commercial strategy and composition of its US organization to current market demand for JETREA® and to ensure it is cash neutral in 2016 • Organization is focused on providing medical and scientific data-driven support to the retina community and is supporting physicians’ efforts to enhance patient awareness of the options available for treating symptomatic VMA • On track for break-even from 2016 onwards JETREA® outside the US • Alcon continues to gain new marketing and reimbursement approvals and to execute commercial launches of JETREA® across Europe and Rest of the World (RoW) • JETREA® is now approved in 53 countries globally and reimbursement is secured in over 20 countries Research & Clinical Development • ThromboGenics remains on track to initiate the CIRCLE study, a Phase II study assessing JETREA®’s ability to generate a posterior vitreous detachment (PVD) in patients with advanced diabetic retinopathy (DR) around the year end of 2015 • A recent report from the American Academy of Ophthalmology projects that by 2020 there will be 1.34 million people in the US with vision-threatening DR • A pre-clinical toxicity study with multiple injections of JETREA® concluded that multiple doses of the drug, given at one month intervals, were well tolerated. This is an important finding as ThromboGenics intends to use multiple doses of JETREA® in the upcoming CIRCLE study. A poster reporting this preclinical study was presented at the European Society of Retina Specialists (EURETINA) conference in Nice 17-20 September • New compounds with distinct mechanisms of action are under evaluation for treatment of diabetic eye diseases • ThromboGenics plans to host an R&D Investor Event in early 2016 at which the Company will provide a review of its clinical and preclinical development pipeline – focused on Diabetic Eye Disease Oncurious • Oncurious plans to commence a Phase I/IIa study with TB-403 in early 2016. The study will assess TB-403 for the treatment of medulloblastoma, the most common form of brain cancer in children Appointments • Baron Philippe Vlerick appointed Non-Executive Director of the Board of ThromboGenics NV at an extraordinary shareholders’ assembly that took place on 20 August 20, 2015 Financial • Cash and investments were €106.6 million as of the end of September 2015, compared with €113.3 million at end of June 2015 and €127.1 million at the end of December 2014 • The current cash resources are expected to enable ThromboGenics to support its business and development plans for at least the next 3 years. Leuven, Belgium – 5 November 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of vitreo-retinal disorders, today issues a business and financial update for the nine months ending 30 September, 2015. ThromboGenics’ strategy is focused on: • Extending the clinical utility of JETREA: Developing JETREA in a significant new indication - Diabetic Retinopathy • Building a pipeline of next generation treatments for diabetic-related vitreo-retinal disorders • Commercializing JETREA (in first approved indication, sVMA/ VMT) in the US and in the rest of the world via partner Alcon (Novartis) to reduce the burden of sVMA on society, and to generate cash to fund our research activities • Within Oncurious NV, further develop TB-403 for treatment of medulloblastoma Dr Patrik De Haes, ThromboGenics’ CEO, said: “In recent months we have made a number of important changes that are designed to ensure ThromboGenics’ future success and to generate returns for our shareholders. We have reduced the size of our US organization and changed our commercial strategy for JETREA® to ensure that our US business will become cash flow neutral from 2016 onwards. While we remain convinced that in time JETREA® could play a key role in a changed standard of treatment for patients with sVMA, this will take time given it will be driven by a combination of new medical data and increasing clinical experience. We are continuing to invest in the clinical development of JETREA® in diabetic retinopathy, a very significant next indication where there is a clear need for improved treatment options. Our Phase II CIRCLE trial in this indication remains on track to initiate around the end of this year. Given our current cash resources of over €100 million, the anticipated royalty income from Alcon and our US organization on track to become cash flow neutral from 2016, we believe that we can support our research and development activities, which are focused on next-generation ophthalmology products for the treatment of diabetic eye disease, over the next 3 years. During this period, we are confident that we will be able to generate the clinical and pre-clinical data needed to demonstrate the value of a number of our pipeline projects.”www.thrombogenics.com/sites/default/f...
Thrombogenics: 'Genoeg cash voor komende drie jaar' 06-11-2015 Sinds de lancering van Jetrea begin 2013 zijn wereldwijd 20.000 patiënten met het Thrombogenics-medicijn behandeld. Voor veel beleggers maakt het evenwel allemaal niet meer uit. Het is al langer duidelijk dat het oogmedicijn niet het goudhaantje is waar iedereen twee jaar geleden op hoopte. Het bedrijf koos om de commercialisering in de VS zelf te doen, maar gooide eerder dit jaar de handdoek in de ring. Het middel blijft op de markt maar Thrombogenics bouwt wel zijn verkoopploeg af. Bedoeling is dat de Amerikaanse activiteiten vanaf 2016 geen geld meer opbranden. 'We zitten op schema', klinkt het. Thrombogenics moet door de tegenslag in de VS bewijzen dat zijn andere medicijnonderzoeken waardevol zijn. Maar het zal nog even duren eer dat duidelijk wordt. Zo start pas eind dit jaar een (fase 2) studie om Jetrea te evalueren als middel tegen diabetische retinopathie. Het bedrijf heeft nog andere stoffen in ontwikkeling die mogelijks een oplossing bieden voor andere oogziektes bij diabetici. Begin 2016 zal Thrombogenics een gedetailleerde uiteenzetting geven over zijn onderzoekspijplijn. Thrombogenics had eind september 106,6 miljoen euro cash. 'Voldoende om minstens drie jaren verder te werken. In die periode zullen we enkele studieresultaten kunnen voorleggen die de waarde van onze technologie kunnen demonstreren.
Thrombogenics licht in duisternis (07-jan) Thrombogenics is het enige aandeel dat een winst van betekenis boekt en dus vormt biotechbedrijf Thrombogenics (3,79 euro, +7,9%) het enige lichtpuntje in al die kommer en kwel. Even ging het aandeel zelfs 14 procent hoger. Het biotechbedrijf dankt die interesse aan een succesje van dochter Oncurious in zijn onderzoek naar een middel tegen hersentumoren. Het FDA, het Amerikaanse agentschap voor de Voeding en de Farma, heeft groen licht gegeven voor de voortzetting van de ontwikkeling van een medicijn voor de behandeling van tumoren bij kinderen. De FDA rondde een onderzoek af naar de veiligheid van het middel. Vorig jaar in april bracht biotechbedrijf Thrombogenics de ontwikkeling van dat kankermedicijn onder in een aparte dochter, Oncurious dus. Het Vlaams Instituut voor Biotechnologie nam daarin ook een minderheidsbelang. De fase I/IIa-studie van TB-403, zoals het middel voorlopig heet, gaat nog dit kwartaal van start. TB-403 wordt ontwikkeled voor relapsed or refractory medulloblastoma, een zeldzame maar levensbedreigende hersentumor die vooral kinderen treft.
twinkletown schreef op 7 januari 2016 11:15 :
Thrombogenics licht in duisternis (07-jan)
Thrombogenics is het enige aandeel dat een winst van betekenis boekt en dus vormt biotechbedrijf Thrombogenics (3,79 euro, +7,9%) het enige lichtpuntje in al die kommer en kwel.
......
Beste Twinkletown, Dank voor je bijdragen. Zo blijft dit forum toch nog wat leven. Ik handel af en toe wat in Thrombo maar heb ook een ijzeren voorraad (nog uit de tijd dat het aandeel heel veel fantasie in zich had). Het is fijn dat er meer mensen zijn die een vinger aan de pols houden in dit aandeel. twee weten meer dan één, nietwaar? En ja, vandaag toch ook wat minder verlies geleden doordat Thrombo ook in portefeuille is. Naast soms wat Tigenix en MDxHealth. Toch mooi die 11% stijging van vandaag. Sluiting op €3,90 en DH €4,03. En 10 x de gemiddelde dagomzet. Er komt weer leven in deze biobrouwerij! Groet, CX
ThromboGenics presenting ophthalmic research findings at Congress of the Academia Ophthalmologica Belgica Leuven, January 8, 2016 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the Company will be presenting two scientific posters at the Congress of the Academia Ophthalmologica Belgica, January 11-13th in Brussels, Belgium. ? Dr. Tine Van Bergen of ThromboGenics will present a poster entitled: PlGF inhibition is as efficacious as VEGF-Trap in reducing scar formation after glaucoma surgery Grant 2014-2015: FRO. The study compares the effect of aflibercept (VEGF-Trap) to PIGF inhibition (5D11D4) on the surgical outcome in a murine model of glaucoma filtration surgery. ? Dr. Koen Willekens of UZ, Ophthalmology, Leuven will present a poster entitled: Robot assisted retinal vein cannulation. The poster covers a study aimed at performing and reporting on in vivo retinal vein cannulations with the help of a dedicated robot. Robot-assisted retinal vein cannulations can overcome practical limitations in the local delivery of antithrombotic drugs (such as ocriplasmin), an experimental therapy for retinal vein occlusions. Dr. Patrik De Haes, ThromboGenics’ CEO, said: “We are pleased to have the opportunity to share our research at the Congress of the Academia Ophthalmologica Belgica this year. The studies being presented demonstrate our ongoing commitment to high-quality technological research in the field of ophthalmology.” - END - For further information please contact: ThromboGenics Wouter Piepers, Global Head of Corporate Communications & IR +32 16 75 13 10 / +32 478 33 56 32wouter.piepers@thrombogenics.com Citigate Dewe Rogerson David Dible/Sylvie Berrebi/Marine Perrier Tel: +44 20 7282 9571david.dible@citigatedr.co.uk About ThromboGenics ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease. The Company’s first product, JETREA® (ocriplasmin), has been approved in 53 countries across the globe. In the US, ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics inc. ThromboGenics signed an agreement with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is planning a Phase II clinical trial with JETREA® in diabetic retinopathy. In addition to JETREA®, the Company is evaluating drug candidates that could potentially deliver a number of next generation treatments for eye disease. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com. Important information about forward-looking statements Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee